A controlled trial of dexamethasone to prevent bronchopulmonary dysplasia in surfactant-treated infants

Pediatrics

Volumn 98, Issue 2, 1996, Pages 204-210

  Rastogi, Alok ^a,b,c   Akintorin, Subuola M ^b,c   Bez, Michelle L ^b,c,d   Morales, Pablo ^b,c,e   Pildes, Rosita S ^b,c,f  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b NW University Medical School   (United States)

^c MA   (United States)

^d OUR LADY OF LOURDES MEDICAL CENTER   (United States)

^e Rockford Memorial Hospital   (United States)

^f ROSALIND FRANKLIN UNIVERSITY OF MEDICINE AND SCIENCE   (United States)

Author keywords

dexamethasone; prevention of bronchopulmonary dysplasia; respiratory distress syndrome; very low birth weight

Indexed keywords

DEXAMETHASONE; SURFACTANT;

AIRWAY PRESSURE; ARTICLE; BRAIN HEMORRHAGE; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; EXTUBATION; HUMAN; INTERMITTENT MANDATORY VENTILATION; LUNG DYSPLASIA; LUNG FUNCTION; MAJOR CLINICAL STUDY; NEWBORN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY DISTRESS SYNDROME; TREATMENT OUTCOME; VERY LOW BIRTH WEIGHT; WEIGHT REDUCTION;

BRONCHOPULMONARY DYSPLASIA; DEXAMETHASONE; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; GLUCOCORTICOIDS; HUMANS; INCIDENCE; INFANT, NEWBORN; INFANT, VERY LOW BIRTH WEIGHT; MALE; PULMONARY SURFACTANTS; RESPIRATION, ARTIFICIAL; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME;

EID: 0029746671     PISSN: 00314005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Hennes HM, Lee MB, Rimm AA, Shapiro DL. Surfactant replacement therapy in respiratory distress syndrome: meta-analysis of clinical trials of single dose surfactant extracts. Am J Dis Child. 1991;145:102-104
2. Meritt TA, Hallman M, Bloom BT, et al. Prophylactic treatment of very premature infants with human surfactant. N Engl J Med. 1986;315:785-790
3. Kendig JW, Notter RH, Cox C, et al. Surfactant replacement therapy at birth: final analysis of a clinical trial and comparisons with similar trials. Pediatrics. 1988;82:756-762
4. Schwartz RM, Luby AM, Scanlon JW, Kellogg RJ. Effect of surfactant on morbidity, mortality, and resource use in newborn infants weighing 500 to 1500 g. N Engl J Med. 1994;330:1476-1480
5. Mugford M, Piercy J, Chalmers I. Cost implications of different approaches to the prevention of respiratory distress syndrome. Arch Dis Child. 1991;66:757-764
6. Jobe AH. Pulmonary surfactant therapy. N Engl J Med. 1993;328:861-868
7. Long W, Thompson T, Sundell H, et al. Effects of two rescue doses of a synthetic surfactant on mortality rate and survival without bronchopulmonary dysplasia in 700 to 1350 gram infants with respiratory distress syndrome. J Pediatr. 1991;118:595-605
8. The OSIRIS Collaborative Group. Early versus delayed neonatal administration of a synthetic surfactant - the judgment of OSIRIS. Lancet. 1992;340:1363-1369
9. Liechty EA, Donovan E, Purohit D, et al. Reduction of neonatal mortality after multiple doses of bovine surfactant in low birth weight neonates with respiratory distress syndrome. Pediatrics. 1991;88:19-28
10. Liggins GC, Howie RN. A controlled trial of antepartum glucocorticoid treatment for prevention of the respiratory distress syndrome in premature infants. Pediatrics. 1972;50:515-525
11. Crowley P, Chalmers I, Keirse M. The effects of corticosteroid administration before preterm delivery: an overview of the evidence from controlled trials. Br J Obstet Gynaecol. 1990;97:11-25
12. National Institutes of Health Consensus Conference. Effect of corticosteroids for fetal maturation on perinatal outcomes. JAMA. 1995;273:413-418
13. Jobe AH, Mitchell BR, Harry Gunkel J. Beneficial effects of the combined use of prenatal corticosteroids and postnatal surfactant on preterm infants. Am J Obstet Gynecol. 1993;168:508-513
14. Hack M, Horbar JD, Malloy MH, Tyson JE, Wright E, Wright L. Very low birth weight outcomes of the National Institute of Child Health and Human Development neonatal network. Pediatrics. 1991;87:587-597
15. Yeh TF, Torre JA, Rastogi A, Anyebuno M, Pildes RS. Early postnatal dexamethasone therapy in premature infants with severe respiratory distress syndrome: a double-blind, controlled study. J Pediatr. 1990;117: 273-282
16. Escobedo MB, Gonzalez A. Bronchopulmonary dysplasia in the tiny infant. Clin Perinatol. 1986;13:315-326
17. Papile L, Burstein J, Burstein R, Koffler H. Incidence and evolution of subependymal and intraventricular hemorrhage: a study of infants with birth weights less than 1500 g. J Pediatr. 1978;92:529-534
18. An international classification of retinopathy of prematurity. Pediatrics. 1984;74:127-133
19. O'Brodovich HM, Mellins RB. Bronchopulmonary dysplasia: unresolved neonatal acute lung injury. Am Rev Respir Dis. 1985;132:694-709
20. Tan KL. Blood pressure in very low birth weight infants in the first 70 days of life. J Pediatr. 1988;112:266-270
21. Mammel MC, Green TP, Johnson DE, Thompson TR. Controlled trial of dexamethasone therapy in infants with bronchopulmonary dysplasia. Lancet. 1983;1:1356-1358
22. Coalson JJ, Kuehl TJ, Escobedo MB, et al. A baboon model of bronchopulmonary dysplasia: pathologic features. Exp Mol Pathol. 1982;37: 335-350
23. Coalson JJ, Kuehl TJ, Prihoda TJ, deLemos RA. Diffuse alveolar damage in the evolution of bronchopulmonary dysplasia in the baboon. Pediatr Res. 1988;24:357-366
24. Stocker JT. Pathology of acute bronchopulmonary dysplasia. In: Bancalari E, Stocker JT, eds. Bronchopulmonary Dysplasia. Washington, DC: Hemisphere; 1988:237-278
25. 2-rich environment: the antioxidant enzymes in the developing rabbit lung. Pediatr Res. 1984;18:240-244
26. Asayama K, Hayashibe H, Dobashi K, et al. Immunohistochemical study on perinatal development of rat superoxide dismutase in lungs and kidneys. Pediatr Res. 1991;29:487-491
27. Davis JM, Metlay L, Penney D, Becker J, Shapiro DL. Lung injury in neonatal piglets from hyperoxia and hyperventilation: effects of prophylactic dexamethasone. Pediatr Res. 1990;27:299. Abstract
28. Avery GB, Fletcher AB, Kaplan M, Brudno S. Controlled trial of dexamethasone in respirator-dependent infants with bronchopulmonary dysplasia. Pediatrics. 1985;75:106-111
29. Durand M, Sardesai S, McEvoy C. Effects of early dexamethasone therapy on pulmonary mechanics and chronic lung disease in very low birth weight infants: a randomized controlled study. Pediatrics. 1995;95: 584-590
30. Sanders RJ, Cox C, Phelps DL, Sinkin RA. Two doses of early intravenous dexamethasone for the prevention of bronchopulmonary dysplasia in babies with RDS. Pediatr Res. 1994;36:122-128
31. Sobel DB, Philip AGS. Prolonged dexamethasone therapy reduces the incidence of cryotherapy for retinopathy of prematurity in infants of less than 1 kilogram birth weight with bronchopulmonary dysplasia. Pediatrics. 1992,90:529-533
32. Batton DG, Roberts C, Trese M, Maisels MJ. Severe retinopathy of prematurity and steroid exposure. Pediatrics. 1992;90:534-536
33. Cummings JJ, D'Eugenio DB, Gross SJ. Controlled trial of dexamethasone in preterm infants at high risk for bronchopulmonary dysplasia. N Engl J Med. 1989;320:1505-1510